Business Wire

ESI Group: A More Inclusive and Safer Industry for Women and Everyone Thanks to Simulation

Share

Regulatory News:

ESI Group (Paris:ESI) (ISIN Code: FR0004110310, Symbol: ESI) is a global partner in simulation and virtual prototyping software for various industries. The company is committed to promoting gender equality through various actions, including the recruitment of women and their professional development within the industry. In addition, the Group is advocating for a swift change in legislation to allow the use of virtual prototyping in certification tests in the automotive industry, with the ultimate goal of ensuring the safety of all users, irrespective of their gender or body shape.

According to the World Economic Forum, women are 47% more likely than men to be seriously injured in a car accident. The study of the Insurance Institute of Highway Safety (IIHS) published in 2021 underlines that women have a mortality rate 20 to 28% higher than men during a road accident, a situation explained in part because of the poor consideration of female morphology in crash tests.

Florence Barré, Women@ESI General Delegate and Chief of Staff to Cristel de Rouvray, CEO of ESI Group: " The role of digitization in ensuring highway safety cannot be overstated. By incorporating diverse morphologies in simulations, virtual prototyping can better protect the entire population. Although the automotive industry has widely adopted virtual prototyping, the use of virtual human models that account for a wide range of morphologies remains optional. Therefore, legislators must take an active role in encouraging the systematic adoption of these practices to ensure optimal safety for all users, regardless of their gender or body shape."

Crash tests that no longer correspond to the reality of society

The current system that we have inherited today has remained relatively unchanged for the past 50 years. Mandatory physical tests in the automotive industry no longer reflect the reality of modern society. Shockingly, only one out of the five dummy models used in crash tests until recently was designed to represent female physiology. This particular model, created in the late 1980s, was based on just 5% of the female population and was mostly used in the front and rear passenger positions, with very little consideration for the driver's seat in regulatory test scenarios.

Towards a major breakthrough?

In a significant milestone for both technological advancement and industry awareness, a team of Swedish engineers announced the creation of the world's first female crash test dummy late last year. This achievement highlights the increasing importance of gender inclusion and equality, which are rapidly gaining traction worldwide. However, the question remains: how can we ensure that this breakthrough is accessible and available to all?

The use of digital human models

ESI Group firmly believes that regulatory evolution is necessary to encourage the adoption of agile and inclusive methods, rather than relying solely on physical tests and prototypes as reference tools for passive safety certifications. Moving towards a more virtual and diverse approach enables the representation of current driving practices, including various morphotypes and passenger positions.

Virtual prototyping allows for flexible parameter modifications and facilitates testing on all morphotypes, enabling even more comprehensive results. Additionally, simulation can incorporate morphological diversity in a faster and less expensive manner. Many of ESI Group's industrial partners are already utilizing virtual prototyping to address this challenge. In fact, ESI Group was the first to perform a virtual crash test on the Volkswagen Polo back in 1985, allowing major automotive OEMs to conduct virtual testing of their prototypes instead of costly and time-consuming physical tests.

About ESI Group

Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time, while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval and heavy industry, ESI is present in more than 20 countries, employs 1000 people around the world and reported 2022 sales of €130 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.

For further information, go to www.esi-group.com.

Follow ESI LinkedIn | Facebook | Twitter | YouTube

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

ESI Group
Florence Barré
press@esi-group.com
+33 1 49 78 28 28

Aline Besselièvre
aline.besselievre@gmail.com
+33 6 61 85 10 05

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

REGiMMUNE Limited Licenses the Rights to Develop and Commercialize RGI-2001 To San Fu Biotech in Major Asian Countries1.4.2023 19:18:00 EEST | Press release

REGiMMUNE Limited (REGiMMUNE), a biotech company focused on creating innovative immunotherapies for immune disorders and cancer, and San Fu Biotech (SFB), a subsidiary of San Fu Chemical Co., Ltd. (4755.TW) have entered a licensing agreement to develop and commercialize RGI-2001 for the prophylaxis of acute Graft-versus-host disease (aGvHD) in major Asian countries. RGI-2001, with the novel mechanism to improve existing treatments, is a potentially first-in-class small molecule drug candidate targeted for preventing aGvHD, a life-threatening complication resulting from allogeneic hematopoietic stem cell transplantation (HSCT). GvHD is a systemic disorder that occurs when the graft's immune cells recognize the host as foreign and attack the recipient’s body cells or organs, and leads to skin rash, liver problems, abdominal pain or cramps, diarrhea, and increased risk for infections. Patients undergoing allogeneic HSCT have a high-risk of developing aGVHD associated with significant morb

AriBio Co., Ltd. to Present Biomarker Data for AR1001 from the Mild to Moderate Alzheimer’s Disease Phase 2 Study at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2023)31.3.2023 19:00:00 EEST | Press release

AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer’s disease who were treated with 10mg and 30mg of AR1001. AR1001 is a potent PDE5 inhibitor with preliminary efficacy in cognition, and preclinical effects on neuron apoptosis inhibition, promotion of neurogenesis, increase in neuroplasticity, and stimulation of autophagy to remove toxic proteins. The phase 2 study was a double-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and preliminary efficacy of AR1001 over 26 and 52 weeks of treatment in patients with mild to moderate Alzheimer’s disease. The trial enrolled 210 patients at 21 research centers in the United States. Plasma collected from patients at baseline, week 26 and week 52 was analyzed by Quantarix using the Simoa HD-X analyzer. Meaningful, statistically significant changes were found over 52 weeks of treatm

KANEKA: “Development of Polymer Synthesis Technology by Microorganisms using CO2 as Direct Raw Material” selected as a NEDO Green Innovation Fund Project”31.3.2023 17:09:00 EEST | Press release

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka; hereinafter "Kaneka"), Bacchus Bio innovation Co., Ltd (Headquarters: Kobe-city, Hyogo; President: Mikio Tanji; hereinafter "Bacchus"), JGC Holdings Corporation (Headquarters: Yokohama-city Kanagawa; Chairman and CEO: Masayuki Sato; hereinafter "JGC HD"), and Shimadzu Corporation (Headquarters: Kyoto-city, Kyoto; President: Yasunori Yamamoto; hereinafter "Shimadzu") have announced that the proposal of a joint project, “Development of Polymer Synthesis Technology by microorganisms using CO2 as direct raw material (hereinafter referred to as ‘the Project’)” had been selected by the "Green Innovation Fund Project*1 / Promotion of Carbon Recycling Using CO2 from Biomanufacturing Technology as a Direct Raw Material” as a planned implementation sponsored by the New Energy and Industrial Technology Development Organization (NEDO). This press release features multimedia. View the full release here: https://www.busine

Allianz Appoints Leadership for Allianz Commercial Key Markets31.3.2023 16:11:00 EEST | Press release

As part of the implementation of its ‘Integrated Commercial’ strategy to better serve the full Commercial segment, Allianz Group today announced the leadership for four of its largest Property and Casualty Commercial insurance markets: Australia, France, Germany and the United Kingdom. In each country, the appointed single Commercial lead will represent the integrated Allianz Commercial business and bring to the market Allianz’s full set of solutions for specialty clients, large corporates, and mid-sized companies, simplifying and enhancing the experience of clients and distribution partners. “The appointment of the regional leaders in our core Allianz Commercial markets is an important, concrete step toward realizing our new integrated model, which brings together our Mid Corporate and Large Corporate insurance business for the benefit of our clients and distribution partners,” said Chris Townsend, Member of the Allianz SE Board of Management. Townsend added, “As one face to the marke

Huawei Releases 2022 Annual Report: Steady Operations, Sustainable Survival and Development31.3.2023 12:59:00 EEST | Press release

Huawei released its 2022 Annual Report today. The company reports steady operations throughout 2022, having generated CNY642.3 billion in revenue and CNY35.6 billion in net profits. Huawei continues to strengthen investment in R&D, with an annual expenditure of CNY161.5 billion in 2022, representing 25.1% of the company's annual revenue and bringing its total R&D expenditure over the past 10 years to more than CNY977.3 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230331005166/en/ (Photo: Huawei) "In 2022, a challenging external environment and non-market factors continued to take a toll on Huawei's operations", said Eric Xu, Huawei's Rotating Chairman, at the company's annual report press conference. "In the midst of this storm, we kept racing ahead, doing everything in our power to maintain business continuity and serve our customers. We also went to great lengths to grow the harvest – generating a steady stream

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom